$VACH News

Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG

Voyager Shareholders Approve Merger With VERAXA Biotech, Expected To Go Public On Nasdaq Under 'VRXA' After Merger

Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG

Voyager Acquisition Reports 25.22M Class A Share Redemptions, Equal To 99.67% Of Outstanding Shares, In Connection With VERAXA Biotech Business Combination

Voyager Acquisition Reports 25.22M Class A Share Redemptions, Equal To 99.67% Of Outstanding Shares, In Connection With VERAXA Biotech Business Combination

VERAXA Biotech Shareholders Approve Merger and Issuance of New Shares to Voyager Acquisition Corp.

VERAXA Biotech Secures Shareholder Approval For Merger And New Share Issuance, Moving Closer To Business Combination Closing With Voyager

VERAXA Biotech And Secarna Pharmaceuticals Enters Strategic Research Collaboration To Develop Next-Generation Antibody Oligonucleotide Conjugates

VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC

VERAXA Biotech And Voyager Acquisition File Form F-4 With SEC, Advancing $1.64B Merger Targeting Q4 2025 Close

VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform

VERAXA Showcases BiTAC Platform At ASCO Annual Meeting And BIO International Convention, Prepares For NASDAQ Listing In 2025

VERAXA Leverages Proprietary BiTAC Platform To Develop Highly Specific Dual-Target Oncology Therapies With Less Off-Tumor Toxicity And Enhanced Tumor Specificity

VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer

VERAXA Biotech Joins Forces with OmniAb to Develop Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors

Veraxa to go public in $1.6bn SPAC deal with Voyager

VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

VERAXA Biotech to Merge With Voyager In $1.3B Business Combination, Launching Nasdaq-Listed Oncology Company

Voyager Acquisition opens at $10, IPO priced at $10

Reported Earlier, Voyager Acquisition Prices Of $220M Initial Public Offering Of 22M Units At $10/Unit